Home - Eiger Biopharmaceuticals | Eiger Biopharmaceuticals

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Click here to read the press release.

Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

Click here to read the press release.

ABOUT US

Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and serious diseases with high unmet medical needs and no approved therapies.

In The News

November 9, 2023

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings Company's cash runway expected to extend into the third quarter of 2024 PALO ALTO, Calif. , Nov.

September 12, 2023

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

PALO ALTO, Calif. , Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of

August 14, 2023

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian , MD,

SEE ALL

Innovative Therapies forRare Metabolic Diseases